Apatinib in Refractory Colorectal Cancer

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Study ID
NCT03190616
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • apatinib — DRUG
    apatinib 500mg/qd, 28d/cycle

Study Details

Limited agents have been approved after standard first and second line treatment. Regorafenib and Trifluridine/Tipiracil (TAS-102) are still not approved in China.Apatinib has shown significant efficacy in refractory advanced gastric cancer regarding PFS and OS with controllable toxicity.This study is aimed to explore the efficacy,safety as well as predictive biomarker in advanced colorectal cancer failed to standard therapy in Chinese population.

Key Dates

Start date
Jul 1, 2017
Status verified
Jan 2020
Primary completion
Jun 30, 2019
Completion
Dec 30, 2019

Study Design

Enrollment
54 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: drug,apatinib
    apatinib 500mg/qd, 28d/cycle

Primary Outcome Measure

Progression-free Survival(PFS) [ Time Frame: From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before Mar 30,2019 ]

Related Studies